uniQure N.V.

QURE

$59.97

Name : uniQure N.V.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $3,694,378,240.00

EPSttm : -3.9

uniQure N.V.

$59.97

3.54%

$2.05

Float Short %

15.15

Margin Of Safety %

Put/Call OI Ratio

0.89

EPS Next Q Diff

0.03

EPS Last/This Y

2.18

EPS This/Next Y

0.27

Price

59.93

Target Price

73.73

Analyst Recom

1.15

Performance Q

303.02

Relative Volume

1.36

Beta

0.59

Ticker: QURE

22 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-09-08	QURE	17.44	0.23	0.58	71604
2025-09-09	QURE	17.49	0.24	0.36	72406
2025-09-10	QURE	17.48	0.24	0.18	72712
2025-09-11	QURE	16.94	0.22	1.76	77003
2025-09-12	QURE	16.48	0.23	0.43	77766
2025-09-15	QURE	14.84	0.23	1.71	79475
2025-09-16	QURE	14.47	0.32	0.63	88784
2025-09-17	QURE	14.16	0.33468065546979	9.1054502369668	91467
2025-09-18	QURE	14.74	0.44	6.42	99310
2025-09-22	QURE	13.83	0.29	0.55	88186
2025-09-23	QURE	13.65	0.30	0.71	93494
2025-09-24	QURE	46.82	0.30	1.40	94459
2025-09-25	QURE	52.68	0.71	0.62	126644
2025-09-26	QURE	54.3	0.70	1.07	145015
2025-09-29	QURE	59.44	0.73	0.75	160507
2025-09-30	QURE	58.29	0.90	1.08	156548
2025-10-01	QURE	55.01	0.92	0.95	158957
2025-10-02	QURE	54.47	0.93	0.51	165062
2025-10-03	QURE	54.92	0.92	1.04	167854
2025-10-06	QURE	52.89	0.93	0.48	171503
2025-10-07	QURE	57.92	0.91	0.52	176503
2025-10-08	QURE	60.09	0.89	0.27	181787
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

22 items 1 of 1

23 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-09-08	QURE	17.43	7.4	3.5	-2.71
2025-09-09	QURE	17.48	7.4	-3.0	-2.71
2025-09-10	QURE	17.49	7.4	-2.0	-2.71
2025-09-11	QURE	16.94	7.4	3.8	-2.71
2025-09-12	QURE	16.48	7.4	3.0	-2.71
2025-09-15	QURE	14.84	7.4	18.5	-2.71
2025-09-16	QURE	14.47	7.4	3.2	-2.71
2025-09-17	QURE	14.16	7.4	2.6	-2.71
2025-09-18	QURE	14.75	7.4	-12.1	-2.71
2025-09-19	QURE	13.82	7.4	11.9	-2.75
2025-09-22	QURE	13.83	7.4	-1.9	-2.75
2025-09-23	QURE	13.65	7.4	0.8	-2.75
2025-09-24	QURE	47.50	7.4	-583.3	-2.75
2025-09-25	QURE	52.65	7.4	-19.4	-2.75
2025-09-26	QURE	54.31	8.2	-7.3	-2.73
2025-09-29	QURE	59.47	8.2	-17.0	-2.73
2025-09-30	QURE	58.33	8.2	0.3	-2.73
2025-10-01	QURE	55.00	8.2	6.0	-2.73
2025-10-02	QURE	54.51	8.2	-1.1	-2.73
2025-10-03	QURE	54.96	8.2	-3.7	-2.73
2025-10-06	QURE	52.89	8.2	2.0	-2.73
2025-10-07	QURE	57.97	10.0	-16.9	-2.76
2025-10-08	QURE	59.93	11.0	-7.7	-2.74
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

23 items 1 of 1

23 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-09-08	QURE	-0.35	10.76	19.99
2025-09-09	QURE	-0.35	10.76	19.99
2025-09-10	QURE	-0.35	10.76	19.99
2025-09-11	QURE	-0.35	10.76	18.62
2025-09-12	QURE	-0.35	10.76	18.62
2025-09-15	QURE	-0.35	10.77	18.62
2025-09-16	QURE	-0.35	10.77	18.62
2025-09-17	QURE	-0.35	10.77	18.62
2025-09-18	QURE	-0.35	10.77	18.62
2025-09-19	QURE	-0.35	10.77	18.62
2025-09-22	QURE	-0.35	10.77	18.62
2025-09-23	QURE	-0.35	10.77	18.48
2025-09-24	QURE	-0.38	10.77	18.48
2025-09-25	QURE	-0.38	10.77	16.88
2025-09-26	QURE	-0.38	10.77	16.88
2025-09-29	QURE	-4.35	10.77	16.88
2025-09-30	QURE	-4.35	10.77	16.88
2025-10-01	QURE	-4.35	10.77	16.88
2025-10-02	QURE	-3.90	10.77	15.27
2025-10-03	QURE	-3.90	10.77	15.15
2025-10-06	QURE	-3.68	5.42	15.15
2025-10-07	QURE	-3.68	5.42	15.15
2025-10-08	QURE	-3.68	5.42	15.15
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

23 items 1 of 1

Last Quarter Act. EPS

-0.69

Avg. EPS Est. Current Quarter

-0.77

Avg. EPS Est. Next Quarter

-0.66

Insider Transactions

-3.68

Institutional Transactions

5.42

Beta

0.59

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

1.3

Max Drawdown 5-Year %

-92.5

Target Price

73.73

P/E

Forward P/E

PEG

P/S

257.63

P/B

P/Free Cash Flow

EPS

-3.92

Average EPS Est. Cur. Y

-2.74

EPS Next Y. (Est.)

-2.48

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1387.98

Relative Volume

1.36

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

-7.7

uniQure N.V.

Sector: Healthcare

Industry: Biotechnology

Employees: 209

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

stock quote shares QURE – uniQure N.V. Stock Price stock today

news today QURE – uniQure N.V. stock forecast ,stock prediction 2023 2024 2025

marketwatch QURE – uniQure N.V. yahoo finance google finance

stock history QURE – uniQure N.V. invest stock market

stock prices QURE premarket after hours

ticker QURE fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: QURE

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y